WO1998041240A1 - Methods and compositions for use in gene therapy for treatment of hemophilia - Google Patents
Methods and compositions for use in gene therapy for treatment of hemophilia Download PDFInfo
- Publication number
- WO1998041240A1 WO1998041240A1 PCT/US1998/004790 US9804790W WO9841240A1 WO 1998041240 A1 WO1998041240 A1 WO 1998041240A1 US 9804790 W US9804790 W US 9804790W WO 9841240 A1 WO9841240 A1 WO 9841240A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- aav
- vector
- promoter
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Definitions
- the field of the invention is gene therapy for treatment of diseases involving a deficiency of proteins in the blood stream.
- Hemophilia is a disease of humans and other mammals wherein a gene encoding a blood coagulation factor contains a mutation such that the encoded protein does not function normally in the cascade process.
- hemophilia B is characterized by a mutation in the gene encoding the blood coagulation protein, Factor IX (F.IX).
- F.IX is reviewed in High et al. (1995, "Factor IX” In: Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds., Marcel Dekker, Inc.).
- Adenoviral vectors are well known in gene therapy and have been used to effect expression of high levels of canine factor IX in immunodeficient mice or in immunocompetent mice when the virus is administered in conjunction with immunosuppressive agents.
- adeno viral vectors When adeno viral vectors are administered to immunocompetent mice in the absence of immunosuppressive agents, these vectors induce a strong inflammatory and cytotoxic T lymphocyte (CTL) response (Dai et al., 1995, Proc. Natl. Acad. Sci. USA 92:1401-1405) which negates the beneficial effects of the therapy.
- CTL cytotoxic T lymphocyte
- Retroviral vectors have also been used experimentally as a model for treatment of hemophilia B. However, levels of expression of F.IX from these vectors are reported to be too low to be of therapeutic value (Kay et al., 1993, Science 262:117- 1 19).
- Plasmid DNA which has been injected into mouse muscle has been shown to direct expression of erythropoietin (Epo) (Tripathy et al., 1996, Proc. Natl. Acad. Sci. USA 93:10876-10880), but this method of gene therapy is apparently not sufficiently efficient for the expression of a gene product such as F.IX, which is needed at relatively high levels in the circulation (compared with Epo) to achieve a therapeutic effect.
- Epo erythropoietin
- Adeno-associated virus is an alternative vehicle to adenovirus for delivery of genes to muscle.
- Recombinant AAV rAAV
- rAAV does not contain sequences encoding viral proteins and has the potential to integrate into the chromosomal DNA of the host cell
- rAAV Ribonucleic acid
- Production and purification procedures are now available which facilitate the generation of pure rAAV which is not significantly contaminated by wild-type AAV or helper adenovirus (Skulimowski et al., 1995, supra; Fisher et al., 1996, J. Virol.
- the invention relates to a composition comprising a recombinant adeno- associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination signal.
- the composition further comprises a portion of intron I of a Factor IX gene.
- the portion of intron I of a Factor IX gene is from about 0.3 kb to about 1.7 kb in length.
- the isolated DNA encoding Factor IX comprises a .. mutation which renders Factor IX encoded thereby incapable of binding to collagen IV.
- mutation in the mutated DNA encodes an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature F.IX.
- composition further comprises a pharmaceutically acceptable carrier.
- promoter/regulatory sequence is selected from the group consisting of the cytomegalovirus immediate early promoter/enhancer, the skeletal muscle actin promoter and the muscle creatine kinase promoter/enhancer.
- the transcription termination signal is the SV40 transcription termination signal.
- kits comprising a vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination signal, and instructions for using the kit.
- the invention also includes a method of treating hemophilia in a mammal.
- the method comprises administering to a muscle tissue of the mammal a composition comprising a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination signal, and a pharmaceutically acceptable carrier.
- the recombinant adeno-associated virus vector is administered by injecting the composition into at least two sites in the muscle tissue. In a preferred embodiment, the recombinant adeno-associated virus vector is administered by injecting the composition into at least six sites in the muscle tissue.
- the recombinant adeno-virus vector is administered at a dose of between about 1 x 10 8 to about 5 x 10 16 viral vector genomes per mammal.
- the mammal is a human and the Factor IX is human Factor IX.
- the promoter/regulatory sequence is selected from the group consisting of the cytomegalovirus immediate early promoter/enhancer, the skeletal muscle actin promoter and the muscle creatine kinase promoter/enhancer.
- the composition further comprises a portion of intron
- the portion of intron I of a Factor IX gene is from about 0.3 kb to about 1.7 kb.
- the isolated DNA encoding Factor IX comprises a mutation which renders Factor IX encoded thereby incapable of binding to collagen IV.
- the mutation in the mutated DNA encodes an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature F.IX.
- the mammal is a human.
- Figure 1 is a series of graphs depicting an analysis of the concentration of human F.IX (hF.IX) in plasma in experimental mice as a function of time following intramuscular (IM) injection of the mice with AAV-hF.IX. Each line represents an individual animal.
- Figure 3 is an image of a Western blot demonstrating the presence of antibodies specific for hF.IX in the plasma of C57BL/6 mice following IM injection of various viral vectors.
- Lane 1 represents an animal injected IM with AAV-lacZ, with serum drawn on day 18 post-injection.
- Lane 2 represents an animal injected IM with recombinant adenovirus-hF.IX (Walter et al., 1996, Proc. Natl. Acad. Sci. USA 93:3056-3061), with serum drawn on day 20 post-injection.
- Lanes 3-10 represent animals injected IM with AAV-hF.IX.
- Lanes 3- 7 represent the same animal analyzed at days 1 1, 18, 32, 54, and 60 post-injection.
- Lanes 8-10 represent different animals analyzed at day 18 post-injection.
- Figure 4 is a series of images depicting immunofluorescence staining (with antibody to hF.IX) of the tibialis anterior muscle of C57BL/6 mice.
- Panel A represents uninjected muscle.
- Panels B, C and D represent muscle stained at three months post-injection with AAV-hF.IX.
- 3.3 x 10'° viral vector genomes were inoculated per injection site. The magnification is 200 x.
- Figure 5 is a series of images depicting immunofluorescence staining of muscle sections of the tibialis anterior muscle of C57BL/6 mice injected with AAV- hF.IX. The analysis was performed at three months following injection. Muscle sections were stained simultaneously with FITC-conjugated antibody specific for hF.IX and a rhodamine-conjugated antibody complex directed against collagen IV. Panel A represents fluorescence of FITC (green) showing the presence of hF.IX in muscle fibers and interstitial spaces. Panel B represents fluorescence of rhodamine (red) showing collagen IV in the extracellular matrix of muscle fibers. Panel C represents simultaneous excitation of both fluorescence tags. Note the presence of a yellow signal in the interstitial spaces indicating that hF.IX and collagen IV occupy the same space in the muscle tissue. The magnification is 400 x.
- Figure 6 is an analysis of DNA isolated from muscle injected with AAV-hF.IX.
- Figure 6A is a diagram depicting head-to-tail tandem repeats of two AAV-hF.IX vector genomes.
- AAV inverted terminal repeat (ITR) sequences, CMV promoter/enhancer (CMV), human F.IX cDNA including the coding sequence, and 228-bp of the 3'-untranslated region, a 1.4 kb portion of intron I, simian virus 40 polyadenylation signal (SV40), and the junction site of the two genomes (J) are indicated on the figure.
- ITR inverted terminal repeat
- CMV CMV promoter/enhancer
- human F.IX cDNA including the coding sequence
- 228-bp of the 3'-untranslated region
- a 1.4 kb portion of intron I simian virus 40 polyadenylation signal
- J junction site of the two genomes
- Figure 6B is an image of a Southern blot hybridization analysis of genomic DNA isolated from the muscle of a Rag 1 mouse six weeks post-injection with AAV-hF.IX. A radioactively labeled EcoRV-EcoRI fragment from intron I of hF.IX served as a probe. Lane 1 represents pAAV-FIX plasmid DNA. Lanes 2 and 3 represent DNA isolated from muscle injected with AAV-hF.IX. Lanes 4 and 5 represent DNA isolated from an uninjected animal. Lanes 1, 2 and 4 represent DNA digested with EcoRV. Lanes 3 and 5 represent undigested DNA.
- FIG. 6C is an image of Southern blot hybridization of junction fragments of head-to-tail concatamers of AAV-hF.IX amplified by PCR. PCR products amplified from genomic DNA using primer pair 005-013 (odd numbered lanes) or primer pair 005-017 (even numbered lanes) are shown. Lanes 1 and 2 represent an uninjected animal. Lanes 3-6 represent C57BL/6 mice injected IM with
- Lanes 7-10 represent Rag 1 mice injected IM with AAV-hF.IX.
- PCR products were obtained from DNA obtained from tibialis anterior (lanes 3, 4, 7 and 8) or quadriceps (lanes 5, 6, 9 and 10) muscle DNA.
- Lanes 1 1 and 12 represent PCR products obtained from DNA obtained from the cell line, 10-3.AV 5, which contains .at least two monomer copies of integrated AAV-lacZ arranged head-to-tail. PCR products were separated on a 2% agarose gel before blotting onto a nylon membrane.
- a 0.7 kb Bglll fragment obtained from the CMV promoter served as a probe.
- Genomic muscle DNA was isolated six to eight weeks post-injection.
- Figure 7 is a diagram of AAV-cF.IX, i.e., canine F.IX in an AAV vector.
- FIG 8 is a series of graphs depicting whole blood clotting time (WBCT) as a function of time after intramuscular injection of dog B45 with 8x10", and dog B46 with lxlO 13 AAV-cF.IX, respectively. If the blood sample did not completely clot within 60 min, the WBCT was indicated as 65 min. Asterisks (*) indicate partial clotting. WBCT of untreated hemophilia B dogs is >60 min (dotted line), and of normal dogs ranges from 6-8 min (broken line). Vertical arrows indicate treatment with normal plasma for bleeding episodes.
- Figure 9 is a series of graphs depicting clotting time by activated partial thromboplastin time (aPTT) of plasma samples obtained from dogs B45 and B46. Normal dogs: 13-18 seconds (broken lines). Untreated hemophilia B dogs: 50-80 seconds (dotted lines). Vertical arrows indicate treatment with normal plasma for bleeding.
- aPTT activated partial thromboplastin time
- Figure 10 is a series of graphs depicting plasma levels of canine factor IX after intramuscular injection of hemophilia B dogs B45 and B46 with 8x10" or 1 xl 0' 3 AAV-cF.IX, respectively. Canine factor IX concentrations were measured by ELISA. Vertical arrows indicate treatment with normal plasma for bleeding. The elevated values in B46 from week 9 through week 12 are partially due to treatment with normal plasma.
- Figure 11 is a series of images depicting immunofluorescence staining for cF.IX in skeletal muscle of dog B45. Panel A: Uninjected muscle. Panels B-D: At week 7, tibialis anterior muscle obtained from one site of injection of 5x10 10 AAV-cF.IX.
- Figure 12 is a diagram of AAV-mF.IX, i.e., mouse F.IX in an AAV ⁇ • vector.
- Figure 13 is an image of a Western Blot for detection of antibodies in mouse plasma specific for mF.IX.
- mF.IX was transferred onto a nitrocellulose membrane and was incubated in the presence of various mouse plasma samples followed by incubation with horseradish peroxidase conjugate anti-mouse IgG and ECL detection.
- Lane 1- Plasma obtained from hemophilia B mouse bred on CD-I background that had developed antibodies specific for hF.IX after intravenous injection of Ad-hF.IX. These antibodies cross-reacted with murine factor IX.
- Lanes 2-10 - Plasma obtained from mice injected intramuscularly with AAV-mF.IX.
- the invention is based on the discovery that delivery of hF.IX to the muscle tissue of a mammal using an rAAV vector as a gene delivery vehicle results in long term expression of hF.IX at therapeutic levels in the muscle tissue.
- the expressed protein persists in the plasma of the mammal for long periods of time and therefore is of tremendous therapeutic benefit to a mammal having hemophilia B.
- the invention is not limited solely to the delivery of F.IX for treatment of hemophilia B. Rather, the invention should be construed to include AAV vectors encoding other blood coagulation factors, which factors may be delivered, using the methods of the present invention, to the cells of a mammal having hemophilia for treatment of hemophilia. Thus, the invention should be construed to include: delivery of Factor VIII to a mammal for treatment of hemophilia A (Tuddenham, 1995, "Factor VIII” In: Molecular Basis of Thrombosis and Hemostasis, High and Roberts, eds.,
- Factor XI for treatment of Factor XI deficiency
- Factor XI deficiency delivery of Factor XIII for treatment of Factor XIII deficiency
- each of the above-recited proteins is accomplished by first generating an AAV vector comprising DNA encoding the desired protein and then administering the vector to the mammal.
- the invention should be construed to include AAV vectors comprising DNA encoding any one of Factor XI, Factor VIII, Factor X, Factor VII, Factor XI, Factor XIII or Protein C. Once armed with the present invention, the generation of AAV vectors comprising DNA encoding these proteins will be apparent to the skilled artisan.
- the invention should not be construed to be limited solely to an rAAV vector comprising an isolated DNA encoding a blood coagulation protein.
- the invention should be construed to include rAAV vectors comprising DNA encoding other proteins, which DNA is preferably administered to the muscle tissue of a mammal.
- the invention should be construed to include DNA encoding gene products which are useful for the treatment of other disease states in a mammal.
- DNA and associated disease states include, but are not limited to: DNA encoding glucose-6-phosphatase, associated with glycogen storage deficiency type 1A; DNA encoding phosphoenolpyruvate-carboxykinase, associated with Pepck deficiency; DNA encoding galactose-1 phosphate uridyl transferase, associated with galactosemia; DNA encoding phenylalanine hydroxylase, associated with phenylketonuria; DNA encoding branched chain ⁇ -ketoacid dehydrogenase, associated with Maple syrup urine disease; DNA encoding fumarylacetoacetate hydrolase, associated with tyrosinemia type 1 ; DNA encoding methylmalonyl-CoA mutase, associated with methylmalonic acidemia; DNA encoding medium chain acyl CoA dehydrogenase, associated with medium chain acetyl CoA deficiency; DNA encoding ornithine transcarba
- the invention is also based on the discovery that injection of the hF.IX- encoding rAAV vector of the invention into multiple sites in the muscle tissue of a mammal results in high level, long term expression of hF.IX in the mammal, thereby providing a therapeutic benefit to the mammal.
- the invention is further based on the additional discovery that hF.IX binds to collagen IV in the interstitial spaces in mammalian muscle tissue.
- the , delivery of mutant forms of hF.IX to the muscle tissue of a mammal via the rAAV vector of the invention, which mutant forms do not bind collagen IV, also serves to provide a therapeutic benefit to a mammal having hemophilia.
- the invention includes an rAAV vector comprising an isolated DNA encoding F.IX, or a biologically active fragment thereof, for use in treatment of hemophilia.
- the invention also includes a method of treating a mammal, preferably, a human, having hemophilia B.
- the method comprises administering to the muscle tissue of the mammal the rAAV vector of the invention.
- the rAAV vector of the invention comprises several essential DNA elements. These DNA elements include at least two copies of an AAV ITR sequence, a promoter /enhancer element, a transcription termination signal, any necessary 5' or 3' untranslated regions which flank DNA encoding F.IX or a biologically active fragment thereof.
- the rAAV vector of the invention also includes a portion of intron I.
- the rAAV vector of the invention comprises DNA encoding an F.IX which contains a mutation such that binding of the mutated F.IX to collagen is substantially reduced or eliminated entirely.
- the vector may comprise a promoter/regulatory sequence which comprises a promiscuous promoter which is capable of driving expression of a heterologous gene to high levels in many different cell types.
- promoters include, but are not limited to the cytomegalovirus (CMV) immediate early promoter/enhancer sequences, the Rous sarcoma virus promoter/enhancer sequences and the like.
- CMV cytomegalovirus
- the promoter/regulatory sequence in the rAAV vector of the invention is the CMV immediate early promoter/enhancer.
- the promoter sequence used to drive expression of the heterologous gene may also be an inducible promoter, for example, but not limited to, a steroid inducible promoter, or may be a tissue specific promoter, such as, but not limited to, the skeletal ⁇ -actin promoter which is muscle tissue specific and the muscle creatine kinase promoter/enhancer, and the like.
- promoter/regulatory sequence means a DNA sequence which is required for expression of a gene operably linked to the promoter/regulator sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene in an inducible/repressible or tissue-specific manner.
- promoter/regulatory sequence means a DNA sequence which is required for expression of a gene operably linked to the promoter/regulator sequence. In some instances, this sequence may be the core promoter sequence and in other instances, this sequence may also include an enhancer sequence and other regulatory elements which are required for expression of the gene in an inducible/repressible or tissue-specific manner.
- promoterAAV vector of the invention also comprises a transcription termination signal. While any transcription termination signal may be included in the vector of the invention, preferably, the transcription termination signal is the SV40 transcription termination signal.
- the vector also includes a portion of intron I.
- intron I is a fragment of DNA which includes the 5' end of the intron up to the first PvuII site (at nucleotide number 1098) and the 3' end of the intron beginning at a PvuII site at nucleotide number 5882 and extending to the junction with exon 2 (Yoshitake et al., 1985, Biochemistry 24:3736-3750; Kurachi et al., 1995, J. Biol. Chem. 270:5276-5281; Jallat et al., 1990, EMBO J. 9:3295-3301).
- Inclusion of an intron element in a plasmid or viral vector encoding F.IX may enhance expression of F.IX by 2- to 10-fold compared with expression of F.IX on a plasmid or viral template in the absence of the intron element (Kurachi et al., 1995, supra).
- AAV vectors typically accept inserts of DNA having a defined size range which is generally about 4 kb to about 4.8 kb, and the coding region of the F.IX gene comprises about 1.5 kb. Thus, it is necessary to include additional DNA in the insert fragment in order to achieve the required length of DNA which is acceptable for the AAV vector.
- the F.IX intron I fragment fulfills this requirement while also enhancing expression of F.IX positioned in the background of an AAV vector genome.
- the invention is not limited to the inclusion of intron I sequences in the rAAV vector of the invention, but should be construed to include other intron or other DNA fragment sequences in place of portions of intron I.
- a portion of intron I is meant region of intron I having a nucleotide length of from about 0.3 kb to about 1.7 kb, which region enhances expression of F.IX by at least about 1.5-fold on a plasmid or viral vector template when compared with expression of F.IX in the absence of a portion of intron I.
- the portion of intron I useful in the present invention is about 1.4 kb in length.
- the rAAV vector of the invention also comprises 5' and 3' untranslated regions of DNA which flank the hF.IX DNA sequence.
- the 5' untranslated region flanking the hF.IX sequences is as follows: At the 5' end of the F.IX sequences, the CMV promoter enhancer sequence continues, at its 3' end, until a Kpnl site having the sequence GGTACC.
- a short polylinker sequence follows directly downstream of this region, having the sequence AGATCTCCACC [SEQ ID:1], which is itself followed directly downstream by the hF.IX sequence beginning at amino acid number -46, the codon for which is an ATG following the numbering system recited in Yoshitake et al. (1985, supra).
- the 3' untranslated region flanking the hF.IX sequences is as follows: At the end of the translation stop signal, the first 228 nucleotides of the 3' untranslated sequence of hF.IX are present which are spliced to the SV40 poly A signal sequences.
- the preferred rAAV vector of the invention also comprises isolated DNA encoding F.IX, or a biologically active fragment of F.IX. While the DNA encoding F.IX is preferably hF.IX, the invention should be construed to include all mammalian F.IX sequences which are either known or unknown. Examples of F.IX sequences are recited in the following articles: Yoshitake et al., 1985, supra; Kurachi et al., 1995, supra; Jallat et al., 1990, supra; Kurachi et al., 1982, Proc. Natl. Acad. Sci. USA 79:6461-6464; Jaye et al., 1983, Nucl. Acids Res. 11 :2325-2335; Anson et al., 1984, EMBO J. 3: 1053-1060; Wu et al., 1990, Gene 86:275-278; Evans et al., 1989,
- the invention should be construed to include F.IX genes from mammals other than humans, which F.IX functions in a substantially similar manner to the hF.IX described herein.
- the nucleotide sequence comprising the gene encoding F.IX is about 50% homologous, more preferably about 70% homologous, even more preferably about 80% homologous and most preferably about 90% homologous to the gene encoding hF.IX described herein and whose sequence is provided in Yoshitake et al. (1985, supra).
- the use of the term "DNA encoding" should be construed to include the
- DNA sequence which encodes the desired protein and any necessary 5' or 3' untranslated regions accompanying the actual coding sequence is provided.
- the invention should be construed to include naturally occurring variants or recombinantly derived mutants of wild type hF.IX DNA sequences, which variants or mutants render the protein encoded thereby either as therapeutically effective as full-length hF.IX, or even more therapeutically effective than full-length hF.IX in the gene therapy methods of the invention.
- collagen IV serves to trap hF.IX which is introduced into the muscle tissue of a mammal via an rAAV vector. Some of the hF.IX so introduced is therefore not available for participation in blood coagulation because it is retained in the interstitial spaces in the muscle tissue by collagen IV. It is possible to introduce a mutation into the sequence of hF.IX DNA such that the protein encoded thereby does not bind collagen IV. Such mutants are useful in the gene therapy methods of the invention for the treatment of hemophilia in that they encode a form of hF.IX which is not trapped in the interstitial spaces of the muscle tissue.
- a mutant hF.IX gene which encodes a hF.IX protein comprising the amino acid alanine in place of lysine in the fifth amino acid position from the beginning of the mature protein, is useful in the rAAV vector of the invention to reduce or eliminate binding of hF.IX to collagen IV.
- the invention should also be construed to include DNA encoding variants of hF.IX which retain hF.IX biological activity.
- variants i.e., analogs of proteins or polypeptides of hF.IX, include proteins or polypeptides which have been or may be modified using recombinant DNA technology such that the protein or polypeptide possesses additional properties which enhance its suitability for use in the methods described herein, for example, but not limited to, variants conferring enhanced stability on the protein in plasma and enhanced specific activity of the protein.
- Analogs can differ from naturally occurring proteins or peptides by conservative amino acid sequence differences or by modifications which do not affect sequence, or by both.
- conservative amino acid changes may be made, which although they alter the primary sequence of the protein or peptide, do not normally alter its function.
- Conservative amino acid substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; phenylalanine, tyrosine.
- the amino acid sequence of an hF.IX analog is about 70% homologous, more preferably about 80% homologous, even more preferably about 90% homologous, more preferably, about 95% homologous, and most preferably, at • least about 99% homologous to the amino acid sequence of hF.IX described in
- Homologous refers to the subunit sequence similarity between two polymeric molecules, e.g., between two nucleic acid molecules, e.g., two DNA molecules or two RNA molecules, or between two polypeptide molecules.
- two nucleic acid molecules e.g., two DNA molecules or two RNA molecules
- two polypeptide molecules e.g., two amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, amino acids, or RNA molecules, or between two polypeptide molecules.
- a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous at that position. The homology between two sequences.
- any number of procedures may be used for the generation of mutant or variant forms of F.IX.
- generation of mutant forms of hF.IX which do not bind collagen IV may be accomplished by introducing deletion, substitution or insertion mutations into an F.IX gene residing on a plasmid template using ordinary recombinant DNA methodology described in any molecular biology manual, for example, described in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, NY).
- Mutant F.IX so generated is expressed and the resulting protein is assessed for its ability to bind collagen IV in a collagen IV binding assay such as that described, for example, in Cheung et al. (1996, Proc. Natl. Acad. Sci.
- isolated nucleic acid refers to a nucleic acid sequence, segment, or fragment which has been separated from the sequences which flank it in a naturally occurring state, e.g., a DNA fragment which has been removed from the sequences which are normally adjacent to the fragment, e.g., the sequences adjacent to the fragment in a genome in which it naturally occurs.
- nucleic acids which have been substantially purified from other components which naturally accompany the nucleic acid, e.g., RNA or DNA or proteins, which naturally accompany it in the cell.
- the term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g, as a cDNA or a genomic or cDNA fragment produced by PCR or restriction enzyme digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.
- biologically active F.IX as used herein, is meant an F.IX protein which is capable of mediating the coagulation of blood in a blood coagulation assay.
- Blood coagulation assays are well known in the art and are described, for example, in Walter et al. (1996. supra) and in Hathaway and Goodnight (1993, Laboratory Measurement of Hemostasis and Thrombosis, In: Disorders of Hemostasis and Thrombosis: A Clinical Guide, pp.21-29).
- therapeutic effect as used herein as it relates to F.IX, is meant coagulation of blood in the mammal following a bleed.
- the invention is not limited to the specific rAAV vector exemplified in the experimental examples; rather, the invention should be construed to include any suitable AAV vector, including, but not limited to, vectors based on AAV-1, AAV-3, AAV-4 and AAV-6, and the like.
- Also included in the invention is a method of treating a mammal having hemophilia in an amount effective to provide a therapeutic effect of mediating coagulation of blood in a blood coagulation assay.
- the method comprises administering to the mammal an rAAV vector comprising F.IX.
- the mammal is a human and the rAAV vector comprises hF.IX which optionally comprises a mutation such that amino acid number five (numbered from the beginning of the mature protein) is an alanine instead of a lysine.
- a preparation of rAAV vector comprising F.IX is injected into the muscle tissue of an animal at a single site per dose and in another method of the invention, a preparation of rAAV is injected into the muscle tissue of the animal either simultaneously, or over the course of several hours, at multiple muscle tissue sites.
- a multiple delivery injection device may be used such that different areas of muscle tissue receive the rAAV vector simultaneously.
- the number of viral vector genomes/mammal which are administered in a single injection ranges from about 1 x 10 8 to about 5 x 10 16 .
- the number of viral vector genomes/mammal which are administered in a single injection is from about 1 x 10'° to about 1 x 10' 5 ; more preferably, the number of viral vector genomes/mammal which are administered in a single injection is from about 5 x 10" to about 5 x 10 15 ; and, most preferably, the number of viral vector genomes which are administered to the mammal in a single injection is from about 5 x 10 13 to about 5 x 10 14 .
- the method of the invention comprises multiple site simultaneous injections, or several multiple site injections comprising injections into different muscle sites over a period of several hours (for example, from about less than one hour to about two or three hours) the total number of viral vector genomes administered is identical to that recited in the single site injection method.
- a suspension of virus is injected directly into the muscle.
- a needle is inserted into the muscle tissue of the mammal.
- the vector is injected essentially continuously along the needle track so that a series of intramuscular sites are injected with each injection, each site therefore being at a position further into the muscle tissue than the previous site.
- Each injection will target from about 5 to about 30 sites along the needle track and patients will receive about 50 injections in all.
- the procedure is therefore akin to an acupuncture procedure which is preferably carried out under anesthesia.
- Multiple site injection of rAAV may also be accomplished using a multiple injection device such as that commonly used for the detection of tuberculosis infection.
- the rAAV vector comprising F.IX is suspended in a pharmaceutically acceptable carrier, for example, HEPES buffered saline at a pH of about 7.8.
- a pharmaceutically acceptable carrier for example, HEPES buffered saline at a pH of about 7.8.
- Other pharmaceutically acceptable carriers which are useful include, but are not limited to, glycerol, water, saline, ethanol and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
- the rAAV vector of the invention may also be provided in the form of a kit, the kit comprising, for example, a freeze-dried preparation of vector in a dried salts formulation, sterile water for suspension of the vector/salts composition and instructions for suspension of the vector and administration of the same to the mammal.
- a kit comprising, for example, a freeze-dried preparation of vector in a dried salts formulation, sterile water for suspension of the vector/salts composition and instructions for suspension of the vector and administration of the same to the mammal.
- the invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
- Example 1 Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX After Intramuscular
- mice developed circulating antibodies to hF.IX.
- hF.IX In follow-up experiments in Rag 1 mice, which have a mutation in the recombinase activating gene and thus lack functional B and T cells, similar results were seen upon DNA analysis of muscle, but these mice also demonstrated therapeutic levels (200-350 ng/ml) of hF.IX in the plasma.
- the time course of hF.IX expression demonstrates that levels gradually increase over a period of several weeks before reaching a plateau that is stable at about 6 months after initial injection.
- colocalization of hF.IX and collagen IV in interstitial spaces between muscle fibers was observed. Collagen IV has been identified as an hF.IX binding protein.
- Recombinant AAV was generated by cotransfection of a F.IX cis plasmid (pAAV-FIX) and the trans-acting plasmid pAAV/Ad (Skulimowski et al., 1995, supra) into human embryonic kidney (293) cells infected with an El-deleted adenovirus as described by Fisher et al. (1996, supra).
- pAAV-FIX was derived from psub201 (Skulimowski et al., 1995, supra) and contains the CMV promoter/enhancer, the human F.IX coding sequence including 1.4 kb fragment of intron 1 (Kurachi et al., 1995, supra), and the SV40 polyadenylation signal, flanked by AAV ITR sequences.
- the AAV rep and cap gene functions were supplied in trans by pAAV/Ad.
- El -deleted adenovirus contains a lacZ or alkaline phosphatase reporter gene to facilitate the identification of any potential contamination of rAAV stocks with helper virus.
- AAV- hF.IX particles had a density of 1.37-1.40 g/ml.
- the titer of the purified AAV-hF.IX was determined by slot blot hybridization using a probe specific to either the CMV promoter or intron I sequences. Controls comprise standards of pAAV-hF.IX plasmid DNA of known concentration.
- AAV-hF.IX The ability of AAV-hF.IX to transduce cells in vitro was confirmed by transducing growing HeLa cells and measuring the concentration of hF.IX in the culture supernatant 36 hours post-infection with an ELISA specific for hF.IX (Walter et al., 1996, supra).
- AAV-hF.IX (10' -10 13 genomes/ml) was stored at -79°C in HEPES-buffered saline, pH 7.8, including 5% glycerol.
- Purified AAV-hF.IX routinely lacked detectable amounts of contaminating adenovirus when analyzed by transduction of 293 cells followed by staining for alkaline phosphatase or ⁇ -galactosidase as described by Fisher et al.(1996, supra). Wild-type AAV was detected at ⁇ 1 infectious unit per 10 9 genomes of AAV- hF.IX.
- the assay for wild-type AAV was as follows: 293 cells grown on chamber slides were co-infected with adenovirus and with aliquots of purified AAV- hF.IX. The cells were fixed for immunofluorescence staining at 24 hours post- infection. A mouse monoclonal antibody directed against AAV capsid proteins (American Research Products, Belmont, MA) served as a primary antibody, and anti- mouse IgG (DAKO Corporation, Carpinteria, CA) in a dilution of 1 :40, served as the secondary antibody.
- a mouse monoclonal antibody directed against AAV capsid proteins (American Research Products, Belmont, MA) served as a primary antibody
- anti- mouse IgG (DAKO Corporation, Carpinteria, CA) in a dilution of 1 :40, served as the secondary antibody.
- mice selected for intramuscular injection with rAAV were C57BL/6 (Charles River Laboratories, Wilmington, MA) and B6, 129 and Rag 1
- mice Female mice (4-6 weeks old) were anesthetized with an intraperitoneal injection of ketamine (70 mg/kg) and xylazine (10 mg/kg), and a 1 cm longitudinal incision was made in the lower extremity.
- AAV- hF.IX (2 x 10" or 1 x 10'° viral vector genomes/animal in HEPES-Buffered-Saline, pH 7.8) was injected into the tibialis anterior (25 ⁇ l) and the quadriceps muscle (50 ⁇ l) of each leg using a Hamilton syringe. Incisions were closed with 4-0 Vicryl suture.
- Plasma samples of C57BL/6 mice which were injected IM with AAV- hF.IX were tested for the presence of antibodies against hF.IX using an ELISA.
- Microtiter plates were coated with hF.IX (1 ⁇ g/ml in 0.1 M NaHCO 3 , pH 9.2). Dilute plasma samples (1 : 16) were applied in duplicate, and antibodies reactive with hF.IX were detected using horseradish peroxidase-conjugated anti-mouse IgG (Zymed, San Francisco, CA) at a dilution of 1 :2000. Buffer conditions were as described (Walter et al., 1996, supra). Levels of anti-hF.IX antibody were estimated by comparison of the absorbance values of monoclonal mouse anti-hF.IX (Boehringer Mannheim) diluted to a final concentration of 1 ⁇ g/ml.
- anti-hF.IX antibody was also assessed by Western blot analysis. These were performed as described by Dai et al. (1995, supra), except that a horseradish peroxidase conjugated goat anti-mouse IgG antibody (Boehringer
- PCR reactions were performed in order to amplify head-to-tail junctions of rAAV tandem repeats.
- the forward primer 005 (5'- ATAAGCTGCAATAAACAAGT-3' [SEQ ID:2]) anneals to the SV40 polyadenylation signal (bp position 8014-8033), and reverse primers 013 (5'- CATGGTAATAGCGATGACTA-3' [SEQ ID:3]) and 017 (5'-
- PCR reactions were performed using 100 ng genomic DNA in a total reaction volume of 100 ⁇ l including 1.5 mM MgCl 2 , and 0.5 ⁇ M of primer pair 005/013 or 005/017.
- 35 cycles of the following profile were carried out: denaturation at 94°C for 1 minute, annealing at 52°C for 1 minute, extension at 72°C for 90 seconds (10 minutes during the final cycle).
- PCR products were cloned for DNA sequence analysis using the T/A cloning kit (Invitrogen, San Diego, CA). Southern blot hybridizations were performed using 32 P-dCTP random primed labeled probes specific for the CMV promoter (for hybridization to PCR fragments) or for intron I of hF.IX as present in AAV-hF.IX (for hybridization to genomic mouse DNA).
- the recombinant AAV vector which was chosen for the in vivo experiments contains the human F.IX cDNA, including a portion of intron I, under the transcriptional control of the CMV immediate early gene promoter/enhancer and the SV40 transcription termination signal.
- This expression cassette is flanked by AAV ITR sequences and completely lacks AAV protein coding sequences.
- Figure 4, Panels B-D depicts expression of human F.IX in the muscle fibers of C57BL/6 mice at three months post- injection. Note that hF.IX is present not only in the muscle fibers themselves, but is also present in the interstitial spaces between the fibers where it appears to accumulate.
- AAV-hF.IX was also delivered to the muscle tissue of Rag 1 mice using the procedures described above for the C57BL/6 mice. These mice are homozygous for a mutation in the recombinase activating gene 1. Rag 1 mice are therefore functionally equivalent to severe combined immunodeficiency (SCID) mice and do not produce mature B or T cells.
- SCID severe combined immunodeficiency
- Genomic DNA obtained from injected muscle tissue was isolated at six to eight weeks post-injection.
- the presence of the introduced vector DNA in the tissue was demonstrated by digestion of the DNA with EcoRV, which releases a 1.8 kb fragment from the vector construct including the entire 1.4 kb intron I sequence.
- a probe specific to intron I hybridized to this fragment ( Figure 6B, lanes 2, 3) and did not cross-hybridize to mouse DNA obtained from an uninjected animal (lanes 4, 5).
- Undigested DNA Figure 6B, lane 3 exhibited a hybridization signal in the high molecular weight DNA.
- Figure 4A successfully amplified those sequences in muscle DNA isolated from AAV-hF.IX transduced tissue (tibialis anterior and quadriceps of immunodeficient and immunocompetent animals).
- Primer pair 005-013 amplified fragments that were 1.0 kb and smaller; primer pair 005- 017 amplified fragments that were 1.2 kb and smaller. As expected, these PCR reactions did not generate distinct bands of the sizes noted above, but rather a series of amplification products were generated having a maximum size. This result was predictable due to imprecise joining of AAV genomes present in these tandem repeats
- hF.IX The time course of expression of hF.IX documented herein is quite different from that observed when adenoviral vectors expressing hF.IX are used. In the latter instance, therapeutic levels of hF.IX are achieved almost immediately (Walter et al., 1996, supra; Kay et al., 1994, Proc. Natl. Acad. Sci. USA 91 :2353-2357). However, the immunological consequences of this approach are undesirable. In the case of AAV-hF.IX, the gradual rise in plasma hF.IX levels over a period of weeks indicates that patients preferably should continue the use of hF.IX concentrates for the initial period immediately surrounding intramuscular AAV vector treatment. This is not a barrier to treatment.
- hF.IX The tl/2 of exogenously administered hF.IX is about 12 hours; thus plasma hF.IX levels may return to baseline before rising as a result of expression of the transgene. Further, expression of rAAV-introduced transgenes in muscle tissue persists for long periods if cross-species boundaries are not transgressed (Kessler et al., 1996, supra). For all of these reasons, administration of rAAV vectors expressing hF.IX to patients having hemophilia B is a feasible strategy for treatment of this disease.
- Administration of 8 x 10" AAV-cF.IX in dog B45 resulted in plasma levels of F.IX which were just at the threshold of detection (approximately 1-3 ng canine F.IX/ml of plasma).
- WBCT WBCT
- WBCT was transiently shortened at various time points following vector administration. Beginning at 16 weeks after injection, sustained partial correction of the WBCT was observed; very low levels of plasma cF.IX have been observed to persist for at least 6 months. Immunofluorescence staining of sections obtained from biopsied muscle was performed and expression of cF.IX in the transduced muscle fibers was observed. No evidence for the production of antibodies specific for cF.IX was obtained when Western blotting analysis, ELISA or a coagulation inhibitor screen were performed.
- Intramuscular injection of 1 x 10' 3 AAV-cF.IX into dog B46 resulted in plasma levels of cF.IX of up to approximately 17 ng of cF.IX/ml which was observed at 9 weeks post-injection. Partial correction of the WBCT was first observed at 2 weeks post-injection and was stable thereafter. The shortest WBCT in the absence of treatment with normal plasma (16 minutes) was measured at week 8. The improvements in the clotting time were corroborated by aPTT assay wherein decreases were evident at week 7 post-injection. Again, there was no evidence for the production of antibodies specific for cF.IX.
- Viral vector AAV-cF.IX was generated as diagramed in Figure 7.
- the vector contains AAV inverted terminal repeats (ITR) flanking the following expression cassette: cytomegalovirus immediate early enhancer/promoter (P[CMV]), CMV splice donor/ ⁇ -globin splice acceptor ( ⁇ glob), cF.IX cDNA up to the EcoRI site at nucleotide position 2565, and human growth hormone polyadenylation signal (hGH).
- ITR AAV inverted terminal repeats
- P[CMV] cytomegalovirus immediate early enhancer/promoter
- ⁇ glob CMV splice donor/ ⁇ -globin splice acceptor
- hGH human growth hormone polyadenylation signal
- Transient transfection of 293 cells in the presence of vitamin K (6 ⁇ g/ml medium) was used to demonstrate that the cF.IX construct directed expression and secretion of functional cF.IX.
- the presence of cF.IX was assessed in media at 96 hours post-transfection and was also confirmed by a shortening of aPTT clotting time of F.IX-deficient human plasma after the addition of conditioned media.
- Different preparations of AAV-cF.IX were compared by infection of 293 cells with equal numbers of vector at various multiplicities of infection in the presence or absence of El -deleted adenovirus. The amount of cF.IX produced was> similar for the different preparations tested.
- Some injections included carbon included carbon particles for subsequent particles for visualization and biopsy subsequent of injection sites visualization of injection sites
- the inhibitor screen was scored as positive if the aPTT clotting time was 3 seconds longer than that of the controls (normal dog plasma incubated with imidazolc buffer and pre-treatment hcmophilic dog plasma incubated with normal clog plasma). Neutralizing antibody titer against AAV vector was assessed. Immunofluorescence staining Biopsied muscle obtained from dog B45 was placed in Optimal Cutting TemperatureTM (OCT) (Tissue-TeK®) OCT 4583 Compound, Sakura Finetek, Torrance CA) in a cryovial, snap-frozen in liquid nitrogen-cooled 2-methyl butane for 7-10 seconds and then immediately transferred to liquid nitrogen and subsequently stored at -80°C.
- OCT Optimal Cutting TemperatureTM
- Cryosections of frozen muscle were stained as described herein using rabbit anti-cF.IX at a 1 :100 dilution (Affinity Biologicals) as primary antibody and fluoreseein isothiocyanate (FITC)-conjugated swine anti-rabbit IgG, diluted 1 :30 (Dako Corp.) as secondary antibody. Cryosections were also used for hematoxylin and eosin (H&E) staining.
- Swabs were taken and samples were resuspended in tissue culture medium. Swab samples were: lacrimal, nasal, rectal, saliva, and urine. A serum sample was also drawn. Samples were concentrated to a final volume of 200 ⁇ l using Centricon-100 vials, and DNA was extracted using the Qiamp blood kit (Qiagen). DNA was eluted in 200 ⁇ l TE, and 10 ⁇ l was used for PCR amplification using the AmpliTaq PCR kit
- PCR primers were as follows: upstream primer, 5'-ATA GCA GCT ACA ATC CAG CTA CCA TTC TGC-3 * [SEQ ID:5] based on sequences in the cDNA of cF.IX, and downstream primer, 5'-TGG TAT CCC GTA GTA CAG GAA CAA ACC ACC-3' [SEQ ID:6] derived from sequences of the ⁇ -globin splice acceptor.
- the PCR product amplified by these primers was 698 bp.
- Intramuscular (IM) injection of dog B45 with 8 x 10" AAV-cF.IX resulted in inconsistent effects upon hemostatic parameters.
- Whole blood clotting times (WBCT) were variable, ranging intermittently from approximately 20 minutes to >60 minutes ( Figure 8).
- Activated partial thromboplastin times (aPTT) were greater than 50 seconds, except for a single value at 3 weeks which was 48 seconds ( Figure 9).
- Levels of cF.IX as assessed by ELISA, were at the threshold of detection (1-3 ng/ml) beginning at 3 weeks post vector injection (Figure 10).
- a muscle biopsy of an injection site was performed at 7 weeks after administration and confirmed intramuscular production of cF.IX by specific immunofluorescence staining ( Figure
- Dog B48 received the highest intramuscular dose of AAV-cF.IX (7 x 10' 3 ).
- This dog bled from an injection site following vector administration and received normal canine plasma at day 4.
- Data available at week 4 following injection demonstrated a decreased WBCT (21.5 minutes) and canine factor IX level of 15 ng/ml.
- This dog is still on study and has not yet reached plateau levels.
- this dog transiently synthesized non-inhibitory antibody to cF.IX.
- Dogs B45 and B46 had no measurable neutralizing antibodies specific for the AAV capsid prior to treatment.
- high titers of anti-AAV capsid neutralizing antibodies (10 0 4 ) developed 7 days after vector administration and persisted throughout the test periods (through 17 weeks and 8 weeks for B45 and B46, respectively).
- Virus shedding, as detected by PCR was positive at day 1 in serum, rectal, and saliva samples obtained from dog B45, and from day 1 serum of dog B46. All other samples obtained pre-trcatmcnt and > 1 day after injection were negative.
- WI1C I (l " ⁇ g 8) ⁇ t week 2, partial cl ⁇ tling by 15-20 nun nfler >60 mm during first week, consistently llie start of the assay, but complete clotting sli ⁇ ilencd after week 2.
- Shortest tune in not observed Subsequent WDC I absence ol treatment with normal pi ism i w i inconsistent, w ith partial corrections (18 5 to 16 m at week 8 28 5 mm) nt 8 limepoinls and incomplete cl ⁇ t formation at 8 other points
- Iniimmoriuorcsccnce Canine factor IX production seen in tibialis To be done. staining (Pig. 1 1 ). anterior muscle fibers biopsied on week 7'. Protein lysates of muscle sample were tested by ELIS ⁇ and showed up to 1.8 ng canine factor IX/mg tissue and up to 25 tig canine factor IX/mg protein.
- Viral shedding ⁇ V-cIMX sequences were delected In scrum Positive PCR signal from day 1 serum at day I (strong signal) and rectal and saliva sample. Samples taken prc-injcction an nt samples at day I (weak signals). No signals day 4 and nt weeks 1 and 2 were negative obtained on pre-trcatment samples and on samples from day 4 and weeks I , 2, 3, and 5.
- AAV-EFl ⁇ -cF.IX was generated using ordinary molecular biology technology.
- the vector contains a 2.5 kb fragment of the human elongation factor l ⁇ gene (EFl ⁇ ), which includes the enhancer, promoter, first exon and first intron, and a portion of the non-coding region of exon 2.
- EFl ⁇ human elongation factor l ⁇ gene
- the EFl ⁇ promoter was chosen because vectors containing it exhibit increased transgene expression following portal vein administration. This region of EFl is positioned upstream of the cF.IX cDNA (up to the EcoRI site at nt 1731) and the human growth hormone polyadenylation signal (hGH).
- hGH human growth hormone polyadenylation signal
- the entire expression cassette is flanked by AAV inverted terminal repeats (ITR). The functional integrity of this vector was demonstrated by ELISA analysis of F.IX produced in 293 cells.
- the abdomen of hemophilic dog B44 was aseptically and surgically opened under general anesthesia and a single infusion of 3 x 10 !2 AAV-EFl ⁇ -cF.IX was administered into the portal vein.
- This animal was protected from hemorrhage in the peri-operative period by intravenous administration of normal canine plasma.
- the dog was sedated, intubated to induce general anesthesia, and the abdomen was shaved and prepped. After the abdomen was opened, the spleen was moved into the operative field. The splenic vein was located and a suture was loosely placed proximal to a small distal incision in the vein.
- Blood samples were analyzed as described herein for intramuscular injections.
- AAV-hF.IX intramuscularly to a mammal
- the normal site of F.IX synthesis is the liver.
- a valid concern for any approach based on expression in an ectopic site is whether biosynthesis will result in some change in the protein that will render it nonfunctional or immunogenic, for example, through alterations in post-translational processing.
- AAV-mouse F.IX (mF.IX) was administered to the muscle of three strains of immunocompetent mice, and the mice were assessed to determine whether antibodies to the autologous transgene product were generated. Two methods were used to demonstrate that anti-mF.IX antibodies (i.e., inhibitors) did not develop in the mice. The presence of antibodies to AAV-mF.IX was assessed by Western blotting.
- AAV-mF.IX antibodies were not detected using this method.
- a coagulation inhibitor screen was also used to assess whether inhibitors were synthesized in the mice and again, this test established that inhibitors were not synthesized in these animals.
- the synthesis of mF.IX in mouse muscle resulted in the production of a protein which was viewed by the immune system as being a self protein.
- this approach i.e., the delivery of F.IX to muscle tissue using an AAV vector is a clinically viable method for treatment of hemophilia.
- AAV-mF.IX ( Figure 12) contained two AAV inverted terminal repeats (ITR) flanking the following expression cassette: the cytomegalovirus immediate early enhancer/promoter (P[CMVJ), CMV splice donor/ ⁇ -globin splice acceptor ( ⁇ glob), the 2.7 kb murine factor IX cDNA, and the human growth hormone polyadenylation signal (hGH).
- the mF.IX cDNA (Wu et al., 1990, Gene 86:275-278) contained a number of errors that had been introduced by PCR. Site-directed mutagenesis was used to restore the wild-type sequence, which was confirmed by DNA sequencing.
- mice The quadriceps and tibialis anterior muscles of both hind limbs of the mice were injected with a total dose of lxl 0" AAV-mF.IX as described herein. Litter mates were injected by the same method with 2x10'° AAV-hF.IX. Retro-orbital bleeding was used to collect plasma samples as described (Walter et al., 1996, Proc. Natl. Acad. Sci. USA 93:3056-3061).
- Western blots were performed by separating 100 ng of hF.IX (Mononine ** plasma-derived factor IX, Armour) or mF.IX (purified from tissue culture media obtained from stably transfected 293 cells) on SDS-PAGE gels followed by transfer of the proteins onto Hybond-ECL membrane (Amersham). Blocking was accomplished using BLOTTO (5% non-fat dry milk, 10 mM Tris-HCl, pH 8.0, 2 mM CaCl 2 , 0.05%
- aPTT assay Mouse plasma was collected in citrate buffer during bleeding from the tail vein. Clotting times in the aPTT assay were conducted by mixing 50 ⁇ l of aPTT reagent (Organon Teknika, Durham, NC) with 50 ⁇ l of murine plasma. The mixture was incubated at 37°C for 3 minutes, and 50 ⁇ l of 25 mM CaCl 2 was added. The clotting time was measured using a fibrometer (BBL FibroSystem). Coagulation Inhibitor Screen
- Plasma obtained from a vector injected mouse was mixed with an equal volume of normal pooled murine plasma and was incubated for 2 hours at 37°C. An aliquot was withdrawn and was mixed with aPTT reagent. The inhibitor screen was scored as positive if the aPTT clotting time was 3 seconds longer than that of the control (normal plasma incubated with imidazole buffer).
- mice injected with AAV-mF.IX developed antibody specific for mF.IX when assayed by Western blotting at 18 days and 60 days post-injection ( Figure
- mice which were injected with AAV-F.IX did not synthesize inhibitors directed against F.IX.
- Example 4 Biochemical Analysis of Human Factor IX Produced bv Skeletal Muscle
- the natural site of F.IX synthesis is within hepatocytes.
- the experimental approach described herein targets the myotubes of skeletal muscle as the site of F.IX production.
- Human F.IX is purified from conditioned medium of human myotubes that are maintained in tissue culture following transfection of the cells with AAV-CMV- hF.IX. Preliminary studies performed to date demonstrate that the myotube- synthesized F.IX is correctly processed in these cells at the N-terminus, and is ⁇ - carboxylated.
- the conditioned medium corrects the aPTT when added to human F.IX deficient plasma.
- Example 5 Clinical Protocol Summary for Administration of AAV-hF.IX to Humans
- a generation of clinical research in patients treated with clotting factor concentrate has documented that minimal elevations in the levels of circulating clotting factor are sufficient to prevent much of the morbidity and mortality of the disease.
- the most comprehensive data are contained in the Swedish prophylaxis studies (Lofqvist et al., 1997, J. Int. Med. 241 :395-400) wherein, since 1958, most hemophilia patients in
- the initial study at least twelve patients will be included. These patients will be assigned to groups of three patients each, and each patient within each group will receive the same dose of AAV-hF.IX.
- the first group of patients will receive a total dose based upon results from a study to determine toxicity in rats.
- the rat toxicity study is performed according to accepted animal toxicity study protocols, prior to the initiation of the Phase I clinical trial (Food and Drug Administration Good Laboratory Practices as found in the 21 C.F.R. ⁇ 58).
- the starting dose in patients will be at least 10-fold lower, on a per kilogram basis, than the lowest dose resulting in unacceptable toxicity following administration to rats. If no toxicity is observed at the highest dose administered to rats, the starting dose in human patients will be at least 10-fold lower than this highest dose.
- a second group of patients will be treated at a dose of one log higher than the initial Group 1 patient dose. If no dose limiting toxicity or expression is observed, this schedule will be repeated until expression is observed in the absence of dose limiting toxicity. Thereafter, doses will be escalated by half log increments .. until there is evidence of biological and physiological efficacy in the absence of unacceptable toxicity.
- patients will be infused with a dose of highly purified coagulation F.IX concentrate calculated to raise the F.IX level in the patient to 100%).
- Intramuscular injections will be carried out under anesthesia in the form of conscious sedation according to hospital protocol.
- a volume of 0.5 ml will be administered in each injection site; the vector concentration and number of injection sites will vary in relation to dose.
- approximately six sites will be injected, and in the highest dose group, approximately twenty sites will be injected.
- Patients will be hospitalized for two to three days. Studies in dogs indicate no shedding of vector beyond 24 hours following injection.
- F.IX concentrate to achieve levels of 50% of normal at approximately twelve hours after injection of vector, and every twenty four hours thereafter for three to seven days depending upon clinical evaluation.
- ADDRESSEE PANITCH SCHWARZE JACOBS & NADEL, P.C.
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
- MOLECULE TYPE DNA (genomic)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64586/98A AU745386B2 (en) | 1997-03-14 | 1998-03-12 | Methods and compositions for use in gene therapy for treatment of hemophilia |
JP54061098A JP4289687B2 (en) | 1997-03-14 | 1998-03-12 | Methods and compositions for use in gene therapy for the treatment of hemophilia |
EP98910320A EP1005376B1 (en) | 1997-03-14 | 1998-03-12 | Compositions for use in gene therapy for treatment of hemophilia |
CA002283639A CA2283639A1 (en) | 1997-03-14 | 1998-03-12 | Methods and compositions for use in gene therapy for treatment of hemophilia |
DE69841982T DE69841982D1 (en) | 1997-03-14 | 1998-03-12 | COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA |
AT98910320T ATE486614T1 (en) | 1997-03-14 | 1998-03-12 | COMPOSITIONS FOR USE IN GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4071197P | 1997-03-14 | 1997-03-14 | |
US60/040,711 | 1997-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998041240A1 true WO1998041240A1 (en) | 1998-09-24 |
Family
ID=21912503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/004790 WO1998041240A1 (en) | 1997-03-14 | 1998-03-12 | Methods and compositions for use in gene therapy for treatment of hemophilia |
Country Status (9)
Country | Link |
---|---|
US (3) | US6093392A (en) |
EP (1) | EP1005376B1 (en) |
JP (1) | JP4289687B2 (en) |
AT (1) | ATE486614T1 (en) |
AU (1) | AU745386B2 (en) |
CA (1) | CA2283639A1 (en) |
DE (1) | DE69841982D1 (en) |
ES (1) | ES2355588T3 (en) |
WO (1) | WO1998041240A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999061601A2 (en) * | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
WO2000075279A2 (en) * | 1999-06-09 | 2000-12-14 | Regents Of The University Of Michigan | Nucleotide sequences for gene regulation and methods of use thereof |
WO2001091803A2 (en) * | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
WO2001096587A2 (en) * | 2000-06-13 | 2001-12-20 | The Children's Hospital Of Philadelphia | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
JP2002540175A (en) * | 1999-02-19 | 2002-11-26 | ドウアリング,マシユー・ジエイ | Oral gene therapy for diabetes and obesity |
US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
US7172893B2 (en) | 1998-11-10 | 2007-02-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
US7718424B2 (en) | 1996-09-11 | 2010-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | AAV4 vector and uses thereof |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
WO2011055089A1 (en) * | 2009-11-06 | 2011-05-12 | Universite Claude Bernard | Production of recombinant factor ix in a human hepatocyte cell line |
US8137960B2 (en) | 2003-12-04 | 2012-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Bovine adeno-associated viral (BAAV) vector and uses thereof |
US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
WO2012177778A1 (en) | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
EP2627665A1 (en) * | 2010-10-12 | 2013-08-21 | The Children's Hospital Of Philadelphia | Methods and compositions for treating hemophilia b |
US8637255B2 (en) | 1998-11-05 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
US8927269B2 (en) | 2003-05-19 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US6531455B1 (en) * | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
US20020037867A1 (en) * | 1999-02-26 | 2002-03-28 | James M. Wilson | Method for recombinant adeno-associated virus-directed gene therapy |
US6797505B2 (en) * | 1998-05-27 | 2004-09-28 | Cell Genesys, Inc. | Recombinant AAV vectors for gene therapy of hemophilia A |
WO2000074688A1 (en) * | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
WO2001049118A1 (en) * | 2000-01-03 | 2001-07-12 | Panagenic International, Inc. | Compositions comprising genome segments and methods of using the same |
US7125841B2 (en) * | 2000-11-14 | 2006-10-24 | The University Of Texas Systems | Mutant human factor IX with an increased resistance to inhibition by heparin |
US6794376B2 (en) * | 2000-12-06 | 2004-09-21 | William Beaumont Hospital | Methods and compositions for enhancing diffusion of therapeutic agents through tissue |
US20020159978A1 (en) * | 2001-02-06 | 2002-10-31 | James Allen | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions |
US7220718B2 (en) | 2001-08-03 | 2007-05-22 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Oral treatment of hemophilia |
CN100488981C (en) | 2001-08-24 | 2009-05-20 | 维多利亚大学创新和发展公司 | Proaerolysin containing protease activation sequences and its uses |
US20030198620A1 (en) * | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
US20040092008A1 (en) * | 2002-11-12 | 2004-05-13 | Snyder Richard O. | Recombinant AAV vectors for gene therapy of hemophilia A |
ES2862206T3 (en) | 2003-06-19 | 2021-10-07 | Genzyme Corp | AAV Virions with Decreased Immunoreactivity and Their Uses |
WO2005077333A2 (en) * | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
US20060148742A1 (en) * | 2004-02-26 | 2006-07-06 | Kaye David M | Polynucleotide delivery to cardiac tissue |
US7722596B2 (en) * | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
DK2438931T3 (en) | 2004-09-22 | 2013-12-02 | St Jude Childrens Res Hospital | IMPROVED EXPRESSION OF FACTOR IX IN GENTERAFFECTORS |
US8152786B2 (en) * | 2006-11-07 | 2012-04-10 | Osprey Medical, Inc. | Collection catheter and kit |
US20100041984A1 (en) * | 2008-08-12 | 2010-02-18 | James Edward Shapland | Impedance sensing device and catheter system |
US9050400B2 (en) * | 2008-08-12 | 2015-06-09 | Osprey Medical, Inc. | Remote sensing catheter system and methods |
CA2780362C (en) | 2009-11-09 | 2019-12-24 | University Of Central Florida Research Foundation, Inc. | Administration of plant expressed oral tolerance agents |
IN2012DN04875A (en) * | 2009-12-08 | 2015-09-25 | Health Research Inc | |
US9295816B2 (en) * | 2009-12-09 | 2016-03-29 | Osprey Medical, Inc. | Catheter with distal and proximal ports |
CN102947453A (en) | 2010-01-28 | 2013-02-27 | 费城儿童医院 | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
KR102128248B1 (en) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Lipid nanoparticle compositions and methods for mrna delivery |
EP2741804B1 (en) | 2011-08-11 | 2017-04-26 | Osprey Medical Inc. | Systems and methods for limb treatment |
US11408899B2 (en) * | 2013-07-12 | 2022-08-09 | The Children's Hospital Of Philadelphia | AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies |
US10612041B2 (en) | 2014-03-21 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Genome editing without nucleases |
WO2017100676A1 (en) * | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav8 |
UA126379C2 (en) | 2016-04-15 | 2022-09-28 | Баксалта Інкорпорейтед | Method and device for providing a pharmacokinetic dosage regimen for medicinal products |
US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
TWI753168B (en) | 2017-05-22 | 2022-01-21 | 日商武田藥品工業股份有限公司 | Viral vectors encoding recombinant fix variants with increased expression for gene therapy of hemophilia b |
WO2019083171A2 (en) | 2017-10-26 | 2019-05-02 | 주식회사 큐로진생명과학 | Composition comprising raav containing soluble vegfr-1 derivative cdna for treatment of macular degeneration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2625412B2 (en) * | 1982-08-04 | 1997-07-02 | ブリティッシュ・テクノロジー・グループ・リミテッド | CDNA encoding human factor 9 polypeptide |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US6342390B1 (en) * | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
US5834306A (en) | 1994-12-23 | 1998-11-10 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
US5846528A (en) * | 1996-01-18 | 1998-12-08 | Avigen, Inc. | Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence |
US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
US5817784A (en) | 1996-08-09 | 1998-10-06 | Amgen Inc. | Neurogene |
US5866552A (en) * | 1996-09-06 | 1999-02-02 | The Trustees Of The University Of Pennsylvania | Method for expressing a gene in the absence of an immune response |
KR20000068501A (en) * | 1996-09-06 | 2000-11-25 | 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Method for recombinant adeno-associated virus-directed gene therapy |
CA2266619A1 (en) * | 1996-09-25 | 1998-04-02 | Richard Snyder | Non-invasive administration of adeno-associated viral vectors |
-
1998
- 1998-03-12 US US09/038,910 patent/US6093392A/en not_active Expired - Lifetime
- 1998-03-12 ES ES98910320T patent/ES2355588T3/en not_active Expired - Lifetime
- 1998-03-12 WO PCT/US1998/004790 patent/WO1998041240A1/en active IP Right Grant
- 1998-03-12 JP JP54061098A patent/JP4289687B2/en not_active Expired - Lifetime
- 1998-03-12 EP EP98910320A patent/EP1005376B1/en not_active Expired - Lifetime
- 1998-03-12 AU AU64586/98A patent/AU745386B2/en not_active Expired
- 1998-03-12 CA CA002283639A patent/CA2283639A1/en not_active Abandoned
- 1998-03-12 DE DE69841982T patent/DE69841982D1/en not_active Expired - Lifetime
- 1998-03-12 AT AT98910320T patent/ATE486614T1/en not_active IP Right Cessation
-
2007
- 2007-10-31 US US11/932,017 patent/US7998734B2/en not_active Expired - Fee Related
-
2011
- 2011-07-08 US US13/178,992 patent/US20110263690A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5547932A (en) * | 1991-09-30 | 1996-08-20 | Boehringer Ingelheim International Gmbh | Composition for introducing nucleic acid complexes into higher eucaryotic cells |
Non-Patent Citations (21)
Title |
---|
"Measurement of Hemostasis and Thrombosis", DISORDERS OF HEMOSTASIS AND THROMBOSIS: A CLINICAL GUIDE, 1993, pages 21 - 29 |
"Remington's Pharmaceutical Sciences", 1991, MACK PUBLICATION CO. |
ANSON ET AL., EMBO J., vol. 3, 1984, pages 1053 - 1060 |
EVANS ET AL., BLOOD, vol. 74, 1989, pages 207 - 212 |
FUJIKAWA ET AL.: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Factor XI" |
JALLAT ET AL., EMBO J., vol. 9, 1990, pages 3295 - 3301 |
JAYE ET AL., NUCL. ACIDS RES., vol. 11, 1983, pages 2325 - 2335 |
KATAYAMA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 4990 - 4994 |
KOTIN R M: "PROSPECTS FOR THE USE OF ADENO-ASSOCIATED VIRUS AS A VECTOR FOR HUMAN GENE THERAPY", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 05, 1 January 1994 (1994-01-01), US, pages 793 - 801, XP002911111, ISSN: 1043-0342 * |
KURACHI ET AL, J. BIOL. CHEM., vol. 270, 1995, pages 5276 - 5281 |
KURACHI ET AL., PROC. NATL. ACAD. SCI., vol. 79, 1995, pages 6461 - 6464 |
LAI ET AL.: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Factor XIII" |
PENDURTHI ET AL., THROMB. RES., vol. 65, pages 177 - 186 |
PETERSEN ET AL.: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Factor VII" |
ROSS G, ET AL.: "GENE THERAPY IN THE UNITED STATES: A FIVE-YEAR STATUS REPORT", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, US, vol. 07, 10 September 1996 (1996-09-10), US, pages 1781 - 1790, XP002911110, ISSN: 1043-0342 * |
SAKAR ET AL., GENOMICS, vol. 6, pages 133 - 143 |
SUZUKI: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Protein C" |
TUDDENHAM: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Factor VIII" |
WATZKE ET AL.: "Molecular Basis of Thrombosis and Hemostasis", 1995, MARCEL DEKKER, INC., article "Factor X" |
WU ET AL., GENE, vol. 86, 1990, pages 275 - 278 |
YOSHITAKE ET AL., BIOCHEMISTRY, vol. 24, 1985, pages 3736 - 3750 |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8507267B2 (en) | 1996-09-11 | 2013-08-13 | U.S. Dept. of Health and Human Services, National Institutes of Health | AAV4 vector and uses thereof |
US8846389B2 (en) | 1996-09-11 | 2014-09-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | AAV4 vector and uses thereof |
US7718424B2 (en) | 1996-09-11 | 2010-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | AAV4 vector and uses thereof |
WO1999061601A3 (en) * | 1998-05-28 | 2000-02-17 | Us Gov Health & Human Serv | Aav5 vector and uses thereof |
US7479554B2 (en) | 1998-05-28 | 2009-01-20 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 nucleic acids |
WO1999061601A2 (en) * | 1998-05-28 | 1999-12-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav5 vector and uses thereof |
US6984517B1 (en) | 1998-05-28 | 2006-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector and uses thereof |
US9163260B2 (en) | 1998-11-05 | 2015-10-20 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US8637255B2 (en) | 1998-11-05 | 2014-01-28 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US9567607B2 (en) | 1998-11-05 | 2017-02-14 | Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype I nucleic acid sequences, vectors and host cells containing same |
US7172893B2 (en) | 1998-11-10 | 2007-02-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
JP2002540175A (en) * | 1999-02-19 | 2002-11-26 | ドウアリング,マシユー・ジエイ | Oral gene therapy for diabetes and obesity |
EP1581614A2 (en) * | 1999-06-09 | 2005-10-05 | The Regents Of The University Of Michigan | Nucleotide sequences for gene regulation and methods of use thereof |
EP1581614A4 (en) * | 1999-06-09 | 2005-10-05 | Univ Michigan | Nucleotide sequences for gene regulation and methods of use thereof |
WO2000075279A3 (en) * | 1999-06-09 | 2005-09-22 | Univ Michigan | Nucleotide sequences for gene regulation and methods of use thereof |
WO2000075279A2 (en) * | 1999-06-09 | 2000-12-14 | Regents Of The University Of Michigan | Nucleotide sequences for gene regulation and methods of use thereof |
US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
US7201898B2 (en) * | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
JP2004501113A (en) * | 2000-06-01 | 2004-01-15 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Methods and formulations for controlled release of recombinant parvovirus vectors |
WO2001091803A3 (en) * | 2000-06-01 | 2002-05-02 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
US7923436B2 (en) | 2000-06-01 | 2011-04-12 | University Of North Carolina - Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
WO2001091803A2 (en) * | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
WO2001096587A3 (en) * | 2000-06-13 | 2002-05-16 | Philadelphia Children Hospital | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
WO2001096587A2 (en) * | 2000-06-13 | 2001-12-20 | The Children's Hospital Of Philadelphia | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
US9238800B2 (en) | 2003-05-19 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
US8927269B2 (en) | 2003-05-19 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Avian adenoassociated virus and uses thereof |
US9193769B2 (en) | 2003-12-04 | 2015-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bovine adeno-associated viral (BAAV) vector and uses thereof |
US8137960B2 (en) | 2003-12-04 | 2012-03-20 | The United States Of America As Represented By The Department Of Health And Human Services | Bovine adeno-associated viral (BAAV) vector and uses thereof |
US8685722B2 (en) | 2003-12-04 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bovine adeno-associated viral (BAAV) vector and uses thereof |
US9012224B2 (en) | 2004-12-15 | 2015-04-21 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
US9475845B2 (en) | 2009-02-11 | 2016-10-25 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
FR2952374A1 (en) * | 2009-11-06 | 2011-05-13 | Univ Claude Bernard Lyon | PRODUCTION OF RECOMBINANT IX FACTOR IN A HUMAN HEPATOCYTE CELL LINE |
WO2011055089A1 (en) * | 2009-11-06 | 2011-05-12 | Universite Claude Bernard | Production of recombinant factor ix in a human hepatocyte cell line |
US9175280B2 (en) | 2010-10-12 | 2015-11-03 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
EP2627665A4 (en) * | 2010-10-12 | 2014-02-26 | Philadelphia Children Hospital | Methods and compositions for treating hemophilia b |
EP2627665A1 (en) * | 2010-10-12 | 2013-08-21 | The Children's Hospital Of Philadelphia | Methods and compositions for treating hemophilia b |
CN103270046A (en) * | 2010-10-12 | 2013-08-28 | 费城儿童医院 | Methods and compositions for treating hemophilia B |
US9629930B2 (en) | 2010-10-12 | 2017-04-25 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia B |
WO2012177778A1 (en) | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
US10413598B2 (en) | 2014-11-12 | 2019-09-17 | Ucl Business Plc | Factor IX gene therapy |
US11344608B2 (en) | 2014-11-12 | 2022-05-31 | Ucl Business Ltd | Factor IX gene therapy |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US11517631B2 (en) | 2018-08-20 | 2022-12-06 | Ucl Business Ltd | Factor IX encoding nucleotides |
Also Published As
Publication number | Publication date |
---|---|
JP4289687B2 (en) | 2009-07-01 |
DE69841982D1 (en) | 2010-12-16 |
US6093392A (en) | 2000-07-25 |
EP1005376B1 (en) | 2010-11-03 |
ATE486614T1 (en) | 2010-11-15 |
US7998734B2 (en) | 2011-08-16 |
EP1005376A4 (en) | 2004-11-24 |
ES2355588T3 (en) | 2011-03-29 |
EP1005376A1 (en) | 2000-06-07 |
US20110263690A1 (en) | 2011-10-27 |
AU745386B2 (en) | 2002-03-21 |
CA2283639A1 (en) | 1998-09-24 |
JP2001517221A (en) | 2001-10-02 |
AU6458698A (en) | 1998-10-12 |
US20080213222A1 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1005376B1 (en) | Compositions for use in gene therapy for treatment of hemophilia | |
US11896652B2 (en) | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues | |
JP2023106497A (en) | Aav virion with decreased immunoreactivity and use thereof | |
JP6473416B2 (en) | Factor VIII sequence | |
US20100137211A1 (en) | Methods and compositions for intra-articular coagulation proteins | |
McCormack Jr et al. | Helper‐dependent adenoviral gene therapy mediates long‐term correction of the clotting defect in the canine hemophilia A model | |
WO2001096587A2 (en) | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus | |
US20040002159A1 (en) | Methods for the production of chimeric adeno-associated virus (AAV) vectors, compositions of chimeric AAV vectors, and methods of use thereof | |
US20180171357A1 (en) | Self-limiting viral vectors encoding nucleases | |
US20020159978A1 (en) | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions | |
Couto | Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors | |
WO2024060463A1 (en) | Improved human coagulation factor viii gene expression cassette and use thereof | |
AU779514B2 (en) | Methods and compositions for use in gene therapy for treatment of hemophilia | |
AU2005201735B2 (en) | Methods and compositions for use in gene therapy for treatment of Hemophilia | |
CN112533645A (en) | Improvement of clinical parameters by expression of factor VIII | |
US20230149563A1 (en) | Compositions and methods for expressing factor ix for hemophilia b therapy | |
US20230175014A1 (en) | Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity | |
WO2021170784A1 (en) | Gene therapy for maple syrup urine disease | |
AU2022379633A1 (en) | Compositions and methods for expressing factor ix for hemophilia b therapy | |
Chen et al. | Muscle injection of rAAV/mFIX to secrete clotting factor IX corrects the hemorrhagic tendencies in hemophilia B mice | |
Hauck et al. | 746. Genomic Stability of Self-Complementary Recombinant Adeno-Associated Virus 2 in Mouse Muscle | |
Petras et al. | 748. Generation of Novel Double-Stranded AAV Vectors with an Expanded Packaging Capacity Using Linearized 1-AAV ITR DNA Molecules | |
Davidoff et al. | Self complementary adeno-associated virus vectors containing a novel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 64586/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2283639 Country of ref document: CA Ref country code: JP Ref document number: 1998 540610 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2283639 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998910320 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998910320 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 64586/98 Country of ref document: AU |